Scinai Immunotherapeutics (SCNI) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Scinai Immunotherapeutics Ltd., a biopharmaceutical company, has restructured a significant bank loan into equity to secure its Nasdaq listing compliance, expected by August 23, 2024. The company also reported confidence in their contract development and manufacturing organization (CDMO) services, with projected sales growth following positive market engagement and development milestones in its pipeline, including promising results for a psoriasis treatment and strategic partnership pursuits for its NanoAb therapies.
For further insights into SCNI stock, check out TipRanks’ Stock Analysis page.
